Selective inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds.
Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr 19
Antony Galione
04 May 2012
|
New Finding, Novel Drug Target
This article outlines the discovery of two novel membrane-permeant molecules that inhibit cardiac dysrhythmic phenomena by blocking cyclic ADP-ribose (cADPR) synthesis in vitro and in vivo. cADPR is a universal calcium-mobilizing messenger whose principal action is to enhance ryanodine receptor-mediated, calcium-induced calcium...
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.